Yes no update but he still has it as a hold in his core WiMax holdings.

At this price the risk/reward is well worth it. My cost is high but if I did not own this it would be a great time to load up.

I just called Etrade to dump my remaining shares. I am done.
Best of luck to those who are left.

Etrade has done this since almost the begining of the year. If you call them they will let you buy or sell with the same on-line commission price.

OT: yes and I own it. Like DNDN I wated for the move and here it comes. Up almost $1 from the low. I would buy some DNDN to put away and hold if you don't have any. Also buy some INFY, should be a double this summer.

Etrade shows the stock still trading.

MOBILEPRO CORP COM NEW (MOBL: OTC BB)
Technology : Communications Equipment
Last Price Today's Change Bid (Size) Ask (Size) Volume Trade
0.037 +0.005 (+15.62%) 0.0355 x5,000 0.037 x5,000 1,887,846

My thinking exactly. The drug will be approved and big pharma needs a blockbuster like this so I would not be surprised at all. We get over $25 per share on the news alone. Hold tight and add on any dips.

No only small amounts.

Did all the research and I am in today.

Oculus Innovative Sciences, Inc.
1129 North McDowell Boulevard
Petaluma, CA 94954
United States - Map
Phone: 707-782-0792
Fax: 707-283-0551
Web Site: http://www.oculusis.com

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 81

BUSINESS SUMMARY
Oculus Innovative Sciences, Inc. engages in the development, manufacture, and marketing of a family of products intended to prevent and eliminate infection in acute and chronic wounds. It is developing a platform technology, Microcyn, a nontoxic, superoxidized water-based solution that is designed to eliminate a range of pathogens, including viruses, fungi, spores, and antibiotic resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus, and Vancomycin-resistant Enterococcus or bleach-resistant bacteria, which cause disease or inhibit the healing in both acute and chronic wounds. Microcyn technology-based products have received three U.S. FDA 510(k) clearances as a medical device in wound cleaning, or debridement, lubricating, moistening, and dressing; and the CE Mark or European Union certification for wound cleaning and reduction of microbial load as a Class IIb medical device. It has also been granted approvals for use as an antiseptic, disinfectant, and sterilant in Mexico; for use in cleaning and debriding in wound management in India; and for moistening, irrigating, cleansing, and debriding skin lesions in Canada. Oculus Innovative is conducting a Phase II pilot study to evaluate the effectiveness of Microcyn in patients with mildly infected diabetic foot ulcers; and a laboratory and animal testing to assess potential applications for Microcyn in various other markets, including respiratory, dermatology, dental, and veterinary markets, as well as has a non-Microcyn based compound in the research and development phase. In addition, the company operates a microbiology contract testing laboratory division that provides consulting and laboratory services. It markets its products under Microcyn, Dermacyn, and Vetericyn trademarks. The company was incorporated in 1999 as Micromed Laboratories, Inc. It changed its name to Oculus Innovative Sciences, Inc. in 2001. The company is headquartered in Petaluma, California.

MobilPro (MOBL)
Antares Pharma(AIS)
Inovio (INO)
Raptor Networks (RPTN)
Integral Technologies (ITKG)
OMNI Energy Services (OMNI)
X-Change Corp (XCHC)
Zeros & Ones (ZROS)

Yes but there should be a premium.

If you remember I have been saying they would probably be bought out but I hope its for much more.

Yup, from Murphy, Silicon Image (SIMG) reported today, after the market close, and I am about to get on the conference call. They did $69.1 million in sales in their March first quarter, up 17% from last year, and seven cents a share pro forma. The consensus was looking for $69 million and five cents. The company guided for $75 million to $79 million in sales in the current quarter, compared to Wall Street expectations for $79 million and eight cents. They said over 500 entities have now adopted HDMI, including 140 in China, compared to 388 this time last year. At the end of the quarter, they had $224 million in cash or $2.50 per share. If anything dramatic happens on the conference call, I will send you a Flash Alert. I don't expect anything, and SIMG remains a Top Buy up to $13 for my $20 target.

Mike Murphy on Mesh Networks

Mesh networking is simply a way to route data between nodes, but a key thing to note is that mesh networks don't have a center. A cellular network runs with a tower at the center of each node, communicating with the cell phones or other devices in its area, and handing the signal off to the next tower as the user moves. A typical corporate computer's network runs with a server, or many servers, at its center. When you connect to the network, your connection is over a local area network that feeds everything into that server, and the server then passes the data on to an internal computer or links outside the company to other servers or the Internet. The Internet itself is a mesh network -- a lot of computers (big servers) talking to each other, rather than a central computer. Your Internet Service Provider at home, or ISP, has the same network architecture model as the corporation; you connect to the ISP, and the ISP then connects to the network, rather than to another, even bigger computer.

Mesh networks are self-organizing, in the sense that they figure out how to route messages according to where connections and bandwidth are available. If one ISP's computer goes down, it does not stop the Internet. If the main East Coast trunk line from New York to Washington is cut by a backhoe, as happened a few years ago, the Internet slowed down just because so much capacity suddenly vanished, but it didn't stop.

The Internet is the biggest mesh network, but these networks can also be very small. For example, sensors smaller than grains of rice can be stirred into a paint can and then painted on a wall. They can use energy from sunlight, room heat or even vibration for power, send out a signal to find each other, self-organize into a network and make the entire wall electrically alive. That wall can then monitor temperatures for fire, or detect the presence of human warmth and turn on and off lights or air conditioning. If someone bangs a chair into the wall and breaks a few hundred sensors, no problem. The rest will reorganize around the dead spot and continue to function.

Between these two extremes lie thousands or tens of thousands of applications for mesh networks. One of the most obvious is to take the existing Wi-Fi spectrum and install Wi-Fi routers that are smart enough to find each other, blanketing a city with a Wi-Fi mesh. But unlike plain vanilla Wi-Fi, this one runs at up to 20 megabits a second -- 30X or 40X most people's DSL speeds, and 5X to 10X cable modem speeds.

That mesh can connect to a computer or directly to a WiMAX backbone that, in turn, connects to an ISP's computer somewhere else. It is even possible to think of the WiMAX backbones forming their own mesh network, ultimately leading to a highly secure facility that creates the connection to the Internet. Think of a less-developed country with rural villages spread all over mountainous territory. Each village gets a low-cost Wi-Fi mesh network that connects to a WiMAX backbone. The WiMAX backbone collects all the towns in an area, and then interconnects them to either a central wireless backbone, or a high-capacity optical line, or directly to computers that connect to the Internet. Nobody has to pull any cable or manage any local servers that need periodic software updates and occasionally break. The network itself tells you where the bottlenecks are, so you don't waste money adding WiMAX send/receive units when the problem is not enough Wi-Fi hotspots, or vice-versa. And the whole thing can deliver high-definition video, voice or data just as if you were in mid-town Manhattan. Video telephones will finally be a reality.

If we are going to add two to three billion people to the Internet quickly, while increasing everyone's available bandwidth by 20X to 50X to handle high-definition video and end dial-up forever -- all of which have to happen -- mesh networks with WiMAX look like the only cost-effective way to do it. With up to six tunable radios on a single chip today, the access points are cheap enough to put almost anywhere.

One of the valuable skills needed to have mesh networks catch on quickly is the ability to get city approvals and contracts to use light poles and such in exchange for free city communications and a dedicated channel for fire and police. Then that company has to raise money to install the network -- roughly $10 to $20 times the number of people in the city -- and manage the operations. If that sounds like MobilePro (MOBL) to you, you are right. As that company sells operations to get Cornell Capital out of their lives, I am hopeful that they will be able to keep the municipal Wi-Fi operation and take advantage of the coming mesh network MegaShift.

Sun Microsystems OKs $3B-Share Buyback >SUNW
Dow Jones Newswires - May 16, 2007 4:15 PM ET

Related Quotes
Symbol Last Chg
SUNW Trade 5.12 -0.02
Real time quote.

DOW JONES NEWSWIRES

Sun Microsystems Inc. (SUNW) after Wednesday's closing bell said it has authorized the buyback of up to $3 billion of its common shares.

The repurchase plan is designed to reduce the dilutive effect of Sun's equity compensation programs and to increase shareholder value, the Santa Clara, Calif.-based company said.

Sun's prior buyback program, which was authorized in February 2001, has been terminated.

The new program doesn't have an expiration date, the company said.

-Katherine Hunt; 415-439-6400; AskNewswires@dowjones.com

Michael Murphy's New World Investor

MobilePro (MOBL) drew thee critical questions, the first from Mike: "I purchased MOBL when you first recommended the stock selling at $0.30 per share. I bought a ton of it in my one IRA. I continue to hold it. Did we miss the mark on this stock or is there some hope that the current management team will successful bring MOBL back from a true penny stock?"

Herb asked: "I notice that Jay Wright , Chief Executive Officer of MOBL just bought 300,000 shares. Do you have anything new to offer on MOBL?"

And Donald followed up with: "When they announced that they were investigating "strategic alternatives", did that mark the beginning of the end?"

As you know, the problem with MOBL is not their operations, it is their financing -- the "death spiral" convertible deal they did with Cornell Capital. Management recently said: "We will, therefore, actively pursue a process with the goal of maximizing the value of our assets, eliminating our debt and returning value to our equity holders."

That's great news -- especially the part about "eliminating our debt." They are going to sell pieces of the business to raise enough money to get rid of Cornell Capital, which is being investigated by the SEC and has its own problems. My hope is that they can settle the debt on better terms than are currently written.

The big question is what they hold on to. If it is the municipal Wi-Fi business, we will have a pure play unencumbered by Cornell Capital, and a really good chance of seeing the stock recover. If it is some other part of the business, I will have to re-evaluate whether it makes sense to continue holding it. I will not abandon you on this stock, even if they sell their Wi-Fi operations. As long as there is a chance of recovery, I will continue to follow it. For now, MOBL remains a hold.

PROVENGE will eventually get approval. The question is when. I think one of the Big Pharma companies will either buy DNDN or partner. Either way we all win. I happen to be lucky because I sold most and plan to hold the rest.

Thanks for the info, I will email Mike Murphy for his opinion on this and post his response. Usually takes a few days.

Michael Murphy, New World InvestorAn Ocean Power Update
Wed, 02 May 2007 14:22:31 ET

Ocean Power Technologies (OPTT -- note the new U.S. symbol; still OPT on the London AIM market) reverse split their stock 1-for-10 on April 23 and did an initial public offering (IPO) in the U.S. that closed on April 25. In London, stocks typically trade or go public around $1, while in the U.S. the "serious money" price is $10, and low prices like London's often put investors off.

Reverse splits are normally bad news for stockholders, because they are done by financially weak companies. Investors, who have held the low-price stock, see the higher numbers and often sell, not even realizing that they have fewer shares. I've almost never seen a reverse split that increased the company's market capitalization after 90 days or so. But I thought there was a good chance that this one might not have an impact, because it was being done for cultural rather than financial reasons. Wrong.

After the reverse split, the stock closed at $23.45 on the London exchange. The company then did the U.S. initial public offering, pricing five million new shares at $20, the bottom of the projected $20 to $22 range. All the shares were sold by the company; there were no selling shareholders. There were 5.2 million shares outstanding before this offering, so they virtually doubled their capitalization and raised $90.1 million net of expenses.

The stock immediately broke from its offering price and plunged as low as $14.37 this morning (equivalent to $1.44 on the old stock). The plunge occurred because this was a badly botched offering by UBS Investment Bank, Banc of America Securities, Bear Stearns and First Albany. They clearly did not explain the company's position well enough to provide support for the stock, and then went ahead with a $20 offering without having a solid enough book for the deal to support OPTT in the aftermarket.

But this offering does not affect the underlying value of OPTT, which gets to keep the $20 a share, or the company's very bright future. I'll have more about this situation in tomorrow's Radar Report, including some news from a recent Congressional hearing on tidal power.

In the March 15 Radar Report, I raised my buy limit on the pre-split stock from $1.50 to $2, which is equivalent to $20 on the post-split stock. The market was saying Ocean Power was worth $125 million before this offering. If I simply add the $90.1 million in cash, and divide by the new number of shares outstanding, it should be worth $21.09 after the offering, as nothing else changed.

Take advantage of the market's confusion and buy OPTT up to $20 for my $40 target. This one should bounce back quickly to the mid $20s -- don't let it get away. I'll be quoting OPTT on the New World Investor portfolio page on the website. If you own the London shares, don't worry -- they will trade in lockstep. If you own the Pink Sheets shares, they should convert automatically to OPTT. If that doesn't happen, contact your broker. You do not have to surrender certificates if by some chance you took delivery of the stock when you bought it. The stock is now dually-listed, so you should be able to sell stock bought in London and held in your account in the U.S., and vice-versa.

Not sure what you want to buy but here is Mike Murphys update from April 26th:
Telkonet (TKO) has been the subject of several emails, such as this one from Michael: "I am concerned about the decline in TKO in recent weeks, and would appreciate your comment. To what do you attribute the decline? Are there any upcoming events such as earnings reports or other announcements that we should look for that will move the stock to the upside?"

I think the decline is entirely attributable to two things. First, there has been a large block of stock overhanging the market that finally traded on Tuesday, under $2 a share. Second, the American Stock Exchange sent TKO a letter in mid-April saying that they needed another independent director to be in compliance with its listing requirements, and also that it needs to automatically refer all related-party transactions to its Audit Committee. TKO took the position that they were in compliance, the AMEX rejected that position, and TKO just appointed a new independent board member and also implemented the Audit Committee rule. I believe this issue is behind them.

The next financial news will be their earnings report in the form of an SEC 8-K filing, probably around May 10. The next press release on new contract wins or an investment by a strategic investor could come anytime. TKO remains a Top Buy under $5 for my $15 target.

Yup! JMO, This is done so the MM's can ret as much stock as they can before a ralyy big move. They want you to sell into the small rise then one day your caught out and its too late.

Depth/Level II for MobilePro Corp 5/8/2007 12:37 PM
MOBILEPRO CORP COM NEW (MOBL: OTC BB)
Technology : Communications Equipment
Current ask is .021
Last Price Today's Change Bid (Size) Ask (Size) Volume Trade
0.02 +0.0017 (+9.29%) 0.0195 x5,000 0.021 x5,000 6,332,168

Time & Sales
Price Size Exch Time
0.019 100000 OBB 12:36:16
0.0185 66317 OBB 12:35:53
0.0185 10000 OBB 12:35:12
0.0185 100000 OBB 12:34:39
0.0185 1000 OBB 12:33:40
0.0185 180298 OBB 12:21:57
0.019 10000 OBB 12:17:02
0.0185 3214 OBB 11:57:28
0.0185 3702 OBB 11:55:46
0.0185 50000 OBB 11:42:39
0.0185 1000 OBB 11:38:40
0.018 1000 OBB 11:38:40
0.0185 10000 OBB 11:26:20
0.018 1000 OBB 11:25:23
0.018 80000 OBB 11:09:16
0.018 5000 OBB 11:04:38
0.018 25000 OBB 11:04:35
0.018 45000 OBB 11:04:03
0.0185 95000 OBB 11:03:01
0.018 5000 OBB 11:02:33
0.018 50000 OBB 11:02:02
0.0178 173000 OBB 10:59:52
0.018 5000 OBB 10:56:53
0.018 5000 OBB 10:56:21
0.018 119000 OBB 10:52:57
0.018 50000 OBB 10:49:56
0.018 10000 OBB 10:45:01
0.018 10000 OBB 10:35:56
0.0175 1100 OBB 10:35:55
0.018 20000 OBB 10:35:54

The last consecutive Green days where Feb 20 thru 22

Date: May 1, 2007


Securities Owned By Josh Levine:

1. Antares Pharma(AIS)

2. Inovio (INO)
3. MobilPro (MOBL)

4. Raptor Networks (RPTN)


The Editor Tobin Smith, directly or indirectly, owned the following securities which are the subject of the commentary, analysis, opinions, advice, or recommendations in, or which are otherwise mentioned in the newsletter, and those stocks are set forth below:

Date: April 3, 2007


Securities Owned By Tobin Smith:

1. Integral Technologies (ITKG)

2. Mobilepro Corp. (MOBL)

3. OMNI Energy Services (OMNI)

4. Raptor Technology (RPTN)

5. X-Change Corp (XCHC)

6. Zeros & Ones (ZROS)

Yes the timing right now is right.

Yes this could be the week we get really BIG news.

Yes they did a quick shakeout then started to buy again.

I don't think its cornell becuse its dropped on very small volume.

We spoke to soon. This is being manipulated so bad to get us to sell. I know a hugh day is comming. Its not today!

Yes I also feel that demand has increased. Looks like many who dumped MOBL earlier may be back.

That what I'm saying really big new that would make the stock worth $100,000,000 market cap would drive this up big. Time will prove me right or wrong. I won't sell into these small 20 to 30 % spikes. For me its all or nothing and I plan on ALL.

I agree. I also believe that when this goes up after big news it will not be 20% or 30% , it will be more like 500% in 1 day.
Yes it does happen and the key is to be in the day it does.

MOBILEPRO CORP COM NEW (MOBL: OTC BB)
Technology : Communications Equipment
Last Price Today's Change Bid (Size) Ask (Size) Volume Trade
0.022 +0.0058 (+35.80%) 0.021 x5,000 0.022 x5,000 5,405,110

MOBILEPRO CORP COM NEW (MOBL: OTC BB)
Technology : Communications Equipment
Last Price Today's Change Bid (Size) Ask (Size) Volume Trade
0.022 +0.0058 (+35.80%) 0.021 x5,000 0.022 x5,000 5,405,110

MOBILEPRO CORP COM NEW (MOBL: OTC BB)
Technology : Communications Equipment
Last Price Today's Change Bid (Size) Ask (Size) Volume Trade
0.022 +0.0058 (+35.80%) 0.021 x5,000 0.022 x5,000 5,405,110

You can look uo any stock on this site. No only the Pink sheets.

No Murphy update

Murphys recent upate.

Dendreon (DNDN) retraced all the way back below $16, not quite getting under my new $15 buy limit. I doubt all the shorts have covered, and there is still a lot of negativity surrounding the May 15 FDA approval date. For all the reasons I went into last week --Provenge combination therapy with Taxotere and the current FDA Commissioner -- I still think Provenge will be approved.

I've had a lot of questions about what to do now with DNDN. So, I'd like to address a number of these concerns now.

John wondered: "Can you let me know how often the short interest position is updated, as the last date I can find is March 12th (approximately 32%) and I'm wondering how big or small that position is now, which will clearly be an influence as whether to buy, hold or sell before May 15. At some point we shall have to revert to fundamentals to value the business."

Short sale data is collected once a month, as close to the 15th as possible. The exchanges report the data about a week later, and NASDAQ reports it a few days after that. I believe the April data will be as of the 16th, and NASDAQ will report it between April 25 and April 27.

Aneil asked: "Do you think FDA approval is priced into Dendreon at this point? What is a realistic price forecast for DNDN after the FDA approves the drug and shorts start to cover? How many short positions do you think are covered by now? Ameritrade does not even allow me to short DNDN at $18 a share."

FDA approval definitely is not priced into the stock at this point -- I would say the stock will hit $25 or $30 on that news. A marketing partnership or two (one for the U.S., one for Europe) would add another $10 a share or so. Short covering is just gravy. My guess is that about half of the shorts were covered by April 16, which is the next "as of" date. But the fact that Ameritrade won't let you short suggests they can't borrow the stock, and if that is true, very few shorts have covered. Knowing how the shorts behave, though, I find that hard to believe.

Incidentally, did you know that at most firms you can short the stock in your margin account while owning it in your cash account? That way, you can put on or take off a short position for price protection, without disturbing your cost basis on the underlying stock.

Michael H. asked a crucial question: "Does the potential approval of Provenge represent a paradigm shift for the FDA in its approval process, and does its rejection of Pharmacyclics' Xcytrin reveal a struggle within the FDA over this shift? Or was the data for Xcytrin significantly poorer or different that it can be distinguished from Provenge in a way that the FDA can avoid setting a confusing or conflicted precedent? Your thoughts and evaluation would be appreciated."

Indeed it does mark a paradigm shift, and the new FDA Commissioner is behind it. There is a real struggle between the process-oriented, old-line bureaucrats in the oncology division and some of the newer folks in biologics, led by the Commissioner. The data for Xcytrin was no worse than for Provenge, but the oncology division won't even consider the application because it barely missed statistical significance. Pharmacyclics said that they will file anyway under protest to force a review. I know Richard Miller, the M.D. and ex-Stanford radiologist who founded and still runs the company, and without even talking to him, I can tell you that he is furious. He is in this business to reduce suffering and save lives.

Xcytrin treats brain metastases from non-small cell lung cancer, in combination with radiation, and a 554-person study showed a 5.4 month improvement in time to neurologic progression, when memory loss started getting worse. Nothing else has worked in these patients. And the treatment has a great safety profile. This is just the kind of -- you should pardon the expression -- crap that the FDA Commissioner is trying to derail. But the oncology division is a notorious quicksand pit for both useful drugs and Commissioners, so I'm sorry to say that I don't think Pharmacyclics will get very far, even if the FDA does review the drug.

Pete asked: "Could you comment on Cell Genesys? I'd like to know what you think about their prospects for approval of the prostate cancer drug that they have under trial. The results seem to be better than what Dendreon had with Provenge. Might this be a company worth investing in? I'd like to know your opinion."

Cell Genesys is developing a vaccine for advanced prostate cancer, but it is many years away from the market. By the time the company does their Phase III trial, the standard of care will be Provenge, not a placebo. By then, Dendreon's "Phase IV" trial in 500 men will be done, and if the results are good enough, Cell Genesys may not have the efficacy needed for approval. I'm also not sure how the company is going to get through the next three years to a potential approval, as they burn close to $30 million a quarter and have only $125 million in cash.

Timothy asked: "What odds do you give for outright approval of Provenge? I was at the panel meeting and although the final tally was great, that didn't happen until the chairman got the definition changed from "establish" to "substantial," and his admonition that this isn't a black and white vote. Doesn't this give the FDA a lot of wiggle room for the decision?"

You are right about what happened, but the FDA already has all the wiggle room it needs if it wants to turn down Provenge. If my read on what Commissioner Andrew von Eschenbach is trying to do is wrong, or he doesn't have enough power to pull it off, the FDA could turn it down. But following last week's analysis, I think the odds of approval are as high as 90%.

Mike wrote: "I have a long position in DNDN that I plan to hold through approval and beyond. What I am wondering is if I should be trying some sort of option strategy (betting on approval of course) to further capitalize on what I think is a very safe bet. Please respond ASAP (time is of the essence) with how to make this play and what the ramifications would be. Also, in your opinion, what are the odds the FDA give their approval before the 15th of May."

Mike, if you are talking about buying calls, I would not buy the May contract. I don't think there's much of a chance that the FDA will make a decision before May 15 -- that just isn't their style -- and they could easily delay a decision for a week or two. That would make May contracts, which expire on May 18, worthless.

Given that, the most attractive contract today probably is the August $15 call (UKOHC), which sells for just over $6 and expires on August 17. But if you already own a good-sized position in the common stock, it may be smarter to put less money on the table and buy the August $22.50 contract (UKOHX) for around $3.75.

I expect the stock to appreciate towards $20 as the date approaches, and at that time it may make sense to buy an insurance put. At that time, the May $15 put (UKOQC) should be under $2 and the $10 put (UKOQB) around 50 cents. You could buy the May put contract, because if the FDA doesn't speak by May 15, the bears will pound the stock. At this time, though, I am not officially recommending any Dendreon options in New World Investor. But if you get the chance before May 15, I recommend that you buy DNDN under $15 for a $40 target.

I could not resist and just added. I thnk we will close Green.